Amphastar Pharms Inc Drug Patent Portfolio
Amphastar Pharms Inc owns 1 orange book drug protected by 4 US patents Given below is the list of Amphastar Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10765602 | Medication delivery systems and methods | 23 Sep, 2039 | Active |
| US10894133 | Device for dispensing a fluid product | 03 Jan, 2038 | Active |
| US10213487 | Nasal powder formulation for treatment of hypoglycemia | 16 Feb, 2036 | Active |
| US6938798 | Fluid or powdery product dispensing device | 03 Jan, 2022 | Expired |
Latest Legal Activities on Amphastar Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amphastar Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Mar, 2024 | US10765602 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 30 Aug, 2023 | US10213487 |
|
Email Notification
Critical
| 30 Aug, 2023 | US10213487 |
|
Email Notification
Critical
| 29 Aug, 2023 | US10765602 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 29 Aug, 2023 | US10765602 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jul, 2022 | US10213487 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 19 Jan, 2021 | US10894133 |
|
Recordation of Patent Grant Mailed
Critical
| 19 Jan, 2021 | US10894133 |
|
Email Notification
Critical
| 30 Dec, 2020 | US10894133 |
|
Issue Notification Mailed
Critical
| 29 Dec, 2020 | US10894133 |
| Dispatch to FDC | 15 Dec, 2020 | US10894133 |
|
Application Is Considered Ready for Issue
Critical
| 15 Dec, 2020 | US10894133 |
|
Issue Fee Payment Received
Critical
| 14 Dec, 2020 | US10894133 |
|
Issue Fee Payment Verified
Critical
| 14 Dec, 2020 | US10894133 |
| Supplemental Papers - Oath or Declaration | 08 Dec, 2020 | US10894133 |
Amphastar Pharms Inc Drug Patents' Oppositions Filed in EPO
Amphastar Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 05, 2020, by Elkington And Fife Llp. This opposition was filed on patent number EP16710352A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP16710352A | Oct, 2020 | ELKINGTON AND FIFE LLP | Patent maintained as amended |
Amphastar Pharms Inc's Family Patents
Amphastar Pharms Inc Drug List
Given below is the complete list of Amphastar Pharms Inc's drugs and the patents protecting them.
1. Baqsimi
Baqsimi is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10765602 | Medication delivery systems and methods |
23 Sep, 2039
(14 years from now)
| Active |
| US10894133 | Device for dispensing a fluid product |
03 Jan, 2038
(13 years from now)
| Active |
| US10213487 | Nasal powder formulation for treatment of hypoglycemia |
16 Feb, 2036
(11 years from now)
| Active |
| US6938798 | Fluid or powdery product dispensing device |
03 Jan, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Baqsimi's drug page